Welcome to Broadline Capital

 

 

Founded in 2005, Broadline Capital is a global alternative investment firm focused primarily on growth capital and impact investments. At Broadline, we're inspired by champions — people of vision and courage — whose ideas can positively change the world, and who are ready to transform their ideas into the next industry-changing company. 

 

When evaluating opportunities, we seek companies that are positioned to thrive as the world continues to transition toward an economy increasingly driven by healthy living and the pursuit of a more efficient and sustainable way of life. We seek category leaders and category creators that are reshaping their industry, and prefer highly-charged sectors where innovation, growth, strong margins, and market consolidation are yielding abundant opportunities.

 

We place emphasis on identifying credible management teams who demonstrate the capability to benefit from our established platform, access to industry expertise, and vast network of relationships built over many years. Broadline's transaction leaders have spent their entire careers building trust-based relationships globally. They have led some of the most creative deals in their market categories. Their collective experience and relationships combine to support Broadline-sponsored companies to develop to the next level. We believe Broadline’s current investing opportunities are among the most exciting on the planet. 

Learn why -

 

New York     |     Miami     |     Columbus     |     Seoul     |     Shanghai

 

 Our Approach 

Broadline's proprietary investment process is designed to stretch alpha at every link of the investment value chain, from our multi-channel deal origination, to our evaluation, structuring and execution. Broadline's past success stems from its multi-channel sourcing, disciplined investment selection, and creative mitigation structuring:

 

  • First, Broadline starts with a "Top-Down" approach to identify targeted categories that are positioned to create broad impact as the world continues to transition toward an economy increasingly driven by healthy living and the pursuit of a more efficient and sustainable way of life, and where a combination of factors are generating an abundance of opportunities. 

 

  • Next, Broadline takes a "Bottom-Up" approach to identify rising category leaders and category creators who are helping to reshape their industry, and whose management teams display the credibility and readiness to develop their business to the next level.  

Broadline seeks less correlated investment risk by pursuing diversification across industries, geographies, transaction sizes, deal structures, development stages, and market capitalizations.

 

  Portfolio Highlights  

We invite you to scroll through case examples of portfolio companies below.   If you are a current Broadline registered investor, please click on the "Investor Login" button at the top of the website for management updates and reports from companies in your investment portfolio and to review examples from our current pipeline of prospective opportunities.

 

Category: Health & Life Sciences

Sub-category: 

Non-INVASIVE Medical Devices

Founded in 2006, EndoSphere is a medical technology company that has developed a first-in-class, non-invasive medical device that endoscopically treats one of the world's largest healthcare issues: Metabolic Diseases including Obesity, Type 2 Diabetes, and Fatty Liver Disease. Endosphere's flagship device, the SatiSphere™ system, is incisionless, reversible and repeatable. In clinical studies, the SatiSphere™ device has enabled Obese patients to achieve significant Excess Weight Loss (EWL) without the need for surgery, providing an alternative to traditional restrictive devices and bariatric surgeries. EndoSphere's portfolio of patent assets is 100% company-owned, and free from any third-party licensing or royalty obligations. EndoSphere received the medical device industry's inaugural "Fierce15" award, named by industry research firm FierceBiotech, which annually recognizes the world's 15 most promising privately-held medical innovations.

  • Novel Device Category: EndoSphere's novel "Endo-Metabolic" devices represent a completely new category of medical devices. Unlike traditional "Restrictive" devices, which work against nature, EndoSphere's Endo-Metabolic devices use the body's natural physiological responses to food intake to accelerate satiety and recalibrate brain-gut metabolic feedback loops. These devices are highly differentiated for their unique ability to amplify a patient's physiologic responses, regulate hormones, recalibrate satiety, and rebalance insulin levels. 

  • Unique Focus on the Duodenum: Unlike other weight-loss treatments, which typically focus on restricting available capacity of the Stomach, EndoSphere focuses on the Duodenum, an important upper section of the small intestine, which is widely recognized as the body's Metabolic Control Center. The Duodenum plays important roles in multiple functions, including: Digestion, Appetite/Satiety regulation, Insulin management, and Drug Delivery.

EndoSphere's original version of its SatiSphere anti-obesity device received CE Mark regulatory approval in 31 countries, and the enhanced version of its product has already entered the clinical stages of development.  For more information, please visit https://www.EndoSphereInc.com.

Category: Environment & Sustainability

Sub-Category:

carbon-free Energy Storage

Founded in 2010, Powermers has developed patented advanced materials that enable the world's first Carbon-Free Lithium-ion Battery Cathodes that demonstrate superior Safety and Performance over batteries using conventional materials. Powermers' performance and safety results have been validated by recognized independent third-party battery testing labs including the US Army Corps of Engineers' Battery Innovation Labs in Champaign, Illinois ("CERL"), and The Ohio State University's Center for Automotive Research Labs in Columbus, Ohio ("OSU CAR"). Proof of data from validation tests conducted by these independent labs showed that batteries replacing conventional Carbon and Binders (the cathode's "deadweight" components) with Powermers' conductive transition-metal polymers resulted in significantly improved safety and performance, without adding steps to the manufacturing process. In fact, Powermers' patented transition-metal polymers demonstrated even higher catalytic functionality than pure noble-metal catalysts including gold, platinum, and palladium. The company believes companies like Samsung and Tesla will greatly benefit from incorporating Powermers' technology into future products to provide a new level of consumer confidence in the Safety and Performance of their products for future generations:

  • Improved Safety: Powermers' technology dramatically improved safety by reducing the Thermal Runaway Risk, a primary cause of high-voltage Lithium-ion batteries over-heating or exploding. In past years, Thermal Runaway Risk has caused billions of losses in value for high-profile companies whose products rely on their battery safety, such as Tesla and Samsung.

  • Improved Performance: Replacing conventional Cathode's "deadweight" components with Powermers' conductive polymers expanded the resulting batteries' Active Material Limit, thereby increasing Specific Energy without sacrificing other KPIs including: Power, Cycle Life, Weight, and Cost per KWH.

  • Ease of Adoption with existing manufacturing processes: Powermers' polymers can be readily integrated into battery manufacturers' existing facilities, as they do not require any significant change to established manufacturing processes, enabling rapid adoption by the industry. Powermers' patented polymers are also affordable, as they contain no precious metals, and yet they serve as highly-efficient catalysts. 

 

The performance and safety results of Powermers' breakthrough battery technology have been published in the industry's peer-reviewed journal, ACS Applied Materials & Interfaces, by American Chemical Society.  Powermers owns 100% of its IP asset portfolio, free from any third-party licensing or royalty obligations. For more information, please visit https://www.Powermers.com.

 

  Our Team  

Broadline's transaction leaders and venture partners are past CEOs and entrepreneurs who founded and led successful companies where they created significant value and negotiated quality exits for themselves and their investors. They have spect their entire careers building trust-based relationships globally, and have led some of the most creative deals in the history of their categories.

 

They understand what it takes to build a business from the ground up, because they've been there.  Staying close to their roots as company operators, they love collaborating with inspired and talented management teams to build something special and realize a shared vision for the company. 

 

  Contact  

At Broadline Capital, we are inspired by champions – people of vision and courage – whose ideas can positively change the world, and who are ready to transform their ideas into the next industry-changing companies.  If you share our perspective, we invite you to join us. We look forward to hearing from you.  Inquiries from Qualified and Accredited Investors are directed to contact us at: Info@BroadlineCapital.com.

   BROADLINE CAPITAL 

MIAMI:  Brickell City Tower, 80 SW 8th St., 20th Floor, Miami, FL 33131

MANHATTAN: 1 Rockefeller Plaza, 11th Floor, New York, NY 10020 

 

Broadline ® is a Registered Trademark.

Copyright © Broadline Capital 2005-2020

All Rights Reserved.